The potential of statins as part of anti-cancer treatment

被引：86

作者：

Sleijfer, S ^{[1
]}

van der Gaast, A ^{[1
]}

Planting, AST ^{[1
]}

Stoter, G ^{[1
]}

Verweij, J ^{[1
]}

机构：

[1] Erasmus Univ, Med Ctr, Dr Daniel Den Hoed Canc Ctr, Dept Med Oncol, NL-3075 EA Rotterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2005年 / 41卷 / 04期

关键词：

statins; anti-tumour activity; solid tumours; drug combinations;

D O I：

10.1016/j.ejca.2004.12.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Statins are known to reduce mortality related to cardiovascular diseases. In recent years, evidence has accumulated that statins also exert anti-tumour activity for which numerous potential underlying mechanisms of action have been suggested. Accordingly, several case-control studies showed a reduction in cancer incidence in patients treated with statins. Furthermore, statins interact synergistically with several anti-tumour treatments in preclinical studies. Until now, only a few clinical studies are available that explore the optimal dose, feasibility, and efficacy of statins applied as single agents to control the growth of existing tumours. Studies investigating statins as part of a multi-drug regimen are completely lacking. Nevertheless, the interesting pre-clinical anti-tumour activity of statins combined with a favourable toxicity profile warrant their further development as anti-tumour agents, in particular as part of multi-drug regimens. (c) 2004 Elsevier Ltd. All rights reserved.

引用

页码：516 / 522

页数：7

共 43 条

[1]

Agarwal B, 1999, CLIN CANCER RES, V5, P2223

[2]

[Anonymous], 2004, LANCET, V363, P1659

[3] 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor (pravastatin) inhibits endothelial cell proliferation dependent on G1 cell cycle arrest [J].